Eli Lilly and Company

“Eli Lilly is a world-class pharmaceutical compounder with a clinically superior GLP-1/GIP franchise, widening moat, elite returns on capital, and a multi-decade reinvestment runway — but at $1,042 and 37x trailing earnings, the stock prices in the base-case outcome with near-zero margin of safety, making expected 5-year forward returns adequate but not exceptional; the right action is to track for a 25-30% pullback to ~$720-800 that would create a genuinely compelling risk/reward entry.”